Skip to main content
OpenTrials
Completed

NCT Number: NCT06099704

Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Moderate to Severe Atopic Dermatitis

Age range

6 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Investigational Site Number : 1240019, Calgary, Alberta, Canada

Loading trial locations.

About this study

The duration of the study for each participant will be of 18 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, 6 years or older at baseline visit (Canada has received the country's regulatory approval for use of Dupixent treating msAD for these ages).
  • Participant is initiating dupilumab as part of routine clinical care through the Dupixent Patient Support Program (PSP) for the treatment of msAD, as per reimbursement criteria. Decision to treat with dupilumab must have been reached prior to and independently of recruitment in the study.
  • Have a physician's diagnosis of msAD.
  • Provided signed informed consent or parental/legally acceptable representative consent and/or participant assent. During the study, subjects will continue to receive maintenance therapies for their AD as clinically indicated and as per usual medical practice.
  • Participant or Parental representative able to understand English and/or Canadian French to complete study-related questionnaires.

Exclusion criteria

  • Participants who have a contraindication to the drug according to the Canadian-specific prescribing information label.
  • Any condition that, in the opinion of the Investigator, may interfere with participant's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the participant from adequately completing the schedule of visits and assessments.
  • Participants currently participating in any interventional clinical trial which modifies participant care.
  • Prior use of Dupixent within 6 months of the baseline visit.
  • Participants not willing to sign the Informed Consent Form.

Treatment and study plan

Primary outcomes

  1. Percentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months

    Time frame: Month 6

    EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score.

  2. Percentage of participants achieving a reduction in EASI of at least 75% at 12 months

    Time frame: Month 12

    EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score.

  3. Percentage of participants achieving a reduction in EASI of at least 75% at 18 months

    Time frame: Month 18

    EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition. Data will be assessed to understand real-world effectiveness of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD using EASI score.

Secondary outcomes

  1. Change from baseline in EASI score

    Time frame: From baseline to 6 months, 12 months, and 18 months post- Dupixent initiation

    Four AD disease characteristics [erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification] will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scoresEASI is a composite index with scores ranging from 0-72. Higher scores indicate worse conditions. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  2. Change from baseline in Body Surface Area of Atopic Dermatitis Involvement (BSA) score

    Time frame: From baseline to 6 months, 12 months, and 18 months post- Dupixent initiation

    BSA affected by AD disease will be assessed for each major section of the body (head, neck, anterior trunk, back, upper limbs, lower limbs, and genitals). It will be reported as a percentage of all major body sections combined. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  3. Change from baseline in Hospital Anxiety and Depression Scale (HADS) score

    Time frame: From baseline to 6 months, 12 months, 18 months post-Dupixent initiation

    HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. The total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher nxiety/depression complains. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  4. Change from baseline in Skin pain/soreness numerical rating scale (NRS)

    Time frame: From baseline to 6 months, 12 months, 18 months post-Dupixent initiation

    Skin pain NRS is a simple assessment tool asking participants to rate their skin pain or soreness using a 0 (No pain or soreness) to 10 (worst possible pain or soreness) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  5. Change from baseline in skin feeling hot or burning NRS

    Time frame: From baseline to 6 months, 12 months, 18 months post-Dupixent initiation

    Skin burning NRS is a simple assessment tool asking participants to rate the sensation of their skin feeling hot or burning sensation using a 0 (Not feeling hot at all) to 10 (feeling extremely hot) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  6. Change from baseline in Peak Pruritus NRS (PP-NRS)

    Time frame: From baseline to 6 months, 12 months, 18 months post-Dupixent initiation

    The peak pruritus NRS is a simple assessment tool asking participants to rate the intensity of their pruritis (itch) using a 0 (no itch) to 10 (worst possible itch) NRS. Data will be assessed to understand (1) the real-world effectiveness of of Dupixent in a heterogeneic population and (2) to characterize disease burden and unmet need in Canadian participants who initiate treatment for msAD.

  7. Percentage of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)

    Time frame: From baseline up to 18 months post-Dupixent initiation

  8. Reasons for discontinuation of Dupixent therapy

    Time frame: From baseline up to 18 months post-Dupixent initiation

    Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD

  9. Mean time to Dupixent discontinuation

    Time frame: From baseline up to 18 months post-Dupixent initiation

    Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD

  10. Median time to Dupixent discontinuation

    Time frame: From baseline up to 18 months post-Dupixent initiation

    Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD

  11. Percentage of participants who initiated Dupixent and remained on treatment

    Time frame: At 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    Data will be assessed to understand the real-world safety of Dupixent in a heterogeneic population of Canadian participants who initiate treatment for msAD

  12. Disease characteristics at baseline: EASI score

    Time frame: At baseline

    EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent. Four AD disease characteristics - erythema, thickness (induration, papulation, and edema), scratching (excoriation), and lichenification - will each be assessed for severity by the Investigator or designee on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement will be assessed as a percentage of each body area assessed: head, trunk, upper limbs, and lower limbs, and converted to a score of 0 to 6. In each body region, the area is expressed as 0 (0%), 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). Total score is the sum of all subscores. EASI is a composite index with scores. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  13. Disease characteristics at baseline: BSA score

    Time frame: At baseline

    BSA affected by AD disease will be assessed for each major section of the body (head, neck, anterior trunk, back, upper limbs, lower limbs, and genitals). It will be reported as a percentage of all major body sections combined. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  14. Disease characteristics at baseline: Time between diagnosis and Dupixent prescription

    Time frame: At baseline

    Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  15. Change from baseline in sleep Disturbance NRS scores post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    Participants will be asked to report the severity of their sleep disturbance during the past 7 days using a 0 (sleep not disturbed at all) to 10 (sleep extremely disturbed) NRS. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  16. Change from baseline in the dermatology life quality index (DLQI)/the Children's Dermatology Life Quality Index (CDLQI) scores post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    The DLQI and CDLQI are a 10-item validated questionnaire to assess the impact of AD disease on quality of life (QoL) in adults and adolescents/pediatrics, respectively. The rating scale range from 0 (not at all) to 3 (very much) 10 items, which assess QoL over the past week. The total score is the sum of all 10-items ranging from 0 to 30; a high score is indicative of a poor QoL. The CDLQI will be used for adolescent participants (aged ≥ 12 to < 18 years) and pediatric participants (aged ≥ 6 to < 12 years); these participants will switch to the DLQI when they turn 18 years of age (if this happens during the study). The CDLQI will be completed with help from participant's caregivers. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  17. Change from baseline in Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD) scores post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    WPAI-AD is designed to assess the impact of AD disease on the participant's productivity. It is a 6-item validated questionnaire to measure effect of your AD disease on your ability to work and perform regular activities over a 7-day recall period. The questionnaire ask participants to recall following types of activities during the previous 7 days: absenteeism (time missed), presenteeism (impairment/ reduced effectiveness), productivity, and activity impairment. Total WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  18. Change from baseline in Work Productivity and Activity Impairment Questionnaire+Classroom Impairment Questions for AD (WPAI-CIQ-AD) scores post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    WPAI-CIQ-AD is designed to asses the impact of AD disease on the participant's productivity. It is a 9-item validated questionnaire to measure participants ability to work, attend classes, and perform regular daily activities during the previous 7 days. Participants are asked to report the work time or classes lost due to AD disease; the impact of eczema on the performance in the workplace, at school, or during university classes; the effect of eczema on other daily activities during the previous 7 days. Total WPAI-AD outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  19. Change from baseline in Dermatitis Family Impact (DFI) score post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    DFI is a 10-question disease-specific measure to assess the impact of AD disease on the QoL of the parents and family members of affected children (≥ 6 to < 18 years)'. The DFI is calculated by summing the score of each question with a maximum total score of 30 (higher scores indicate higher impact on life of family). Caregivers complete the questionnaire for affected children. Data will be assessed to characterize disease burden and unmet need in Canadian msAD participants who initiate treatment with Dupixent.

  20. Concomitant treatments received

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  21. Dupixent dosing regimen

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  22. Most commonly used Dupixent dosing regimens

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  23. Dupixent treatment duration

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  24. Number of gaps in Dupixent treatment

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  25. Longest gap in Dupixent treatment

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  26. Number of missed Dupixent doses over 18 months per participant

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  27. AD treatments to which participants switch when discontinuing dupixent

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  28. Reasons for initiation of new AD treatments

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  29. Reasons for discontinuation and/or switching AD treatments

    Time frame: From baseline up to 18 months

    Data will be assessed to describe real-world treatment patterns in Canadian msAD participants who initiate treatment with Dupixent

  30. Change from baseline in HADS

    Time frame: From baseline to 6 months, 12 months and 18 months post- Dupixent initiation

    HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3. The anxiety/depression score is the sum of the scores of the 7 related items; one can score between 0 and 21 for either anxiety or depression. The total score is the sum of the scores of the 14 items ranging from 0 (no symptoms) to 42 (severe symptoms), with higher scores indicating higher nxiety/depression complains. Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixen.

  31. Change from baseline in sleep disturbance NRS scores post-Dupixent initiation

    Time frame: From baseline to 3 months, 6 months, 12 months and 18 months post- Dupixent initiation

    Participants will be asked to report the severity of their sleep disturbance during the past 7 days using a 0 (sleep not disturbed at all) to 10 (sleep extremely disturbed) NRS. Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent.

  32. Change from baseline in height

    Time frame: From baseline to 6 months, 12 months and 18 months post- Dupixent initiation

    Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent

  33. Change from baseline in weight

    Time frame: From baseline to 6 months, 12 months and 18 months post- Dupixent initiation

    Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent

  34. Change from baseline in BMI

    Time frame: From baseline to 6 months, 12 months and 18 months post- Dupixent initiation

    Data will be assessed to understand patterns and/or changes in non-atopic conditions in Canadian msAD participants who initiate treatment with Dupixent

  35. Number of participants with demographic characteristics

    Time frame: From baseline up to 18 months

    Data will be assessed for all demographic characteristics by age, sex, race and ethnicity, location to understand baseline characteristics and/or changes in Canadian msAD participants who initiate treatment with Dupixent, with co-existing type 2 inflammatory diseases.

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Collaborators

  • Regeneron Pharmaceuticals

Registry information

Official study title

A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis

Acronym: CANDID

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Oct 25, 2023
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.